A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Summary

The study is intended to evaluate the efficacy and safety of 2 different doses of DAP/TOM followed by bepirovirsen in participants living with CHB on standard of care nucleos(t)ide analogue (NA) therapy. The study also aims to identify an optimal dose of DAP/TOM for sequenced therapy with bepirovirsen for further clinical development and to assess the contribution of DAP/TOM to the sequential regimen. The study will also include an optional long-term follow-up (LTFU) extension stage for eligible participants.

Timeline

Start

2024-11-11

Primary completion

2027-05-31

Completion

2030-05-17

Publications

• Hong J, Rajwanshi VK. Antisense oligonucleotides as drugs with both direct and indirect antiviral actions. Antiviral Res. 2025 Aug;240:106219. doi: 10.1016/j.antiviral.2025.106219. Epub 2025 Jun 23.

Drugs

Indications